Accro Bioscience Announces Inclusion of AC-101 tablets in the NMPA CDE's "Caring Plan-Extension" Pilot Program for Rare Disease Drug Development

Accro Bioscience announced that its AC-101 tablets were included in China’s Rare Diseases Innovative Drug Development Encouragement Pilot Program, or “Caring Plan-Extension,” effective September 14, 2026 China Standard Time. The inclusion is a positive regulatory-development milestone for AC-101, though the available article text provides no clinical, commercial, or financial details.